Calcipotriene/betamethasone in the treatment of psoriasis: A review article

Rosita Saraceno, Talia Gramiccia, Pasquale Frascione, Sergio Chimenti

Research output: Contribution to journalArticlepeer-review


Plaque-type psoriasis is a chronic and immune-mediated skin disease affecting ∼1 - 3% of the Caucasian population. Most cases are of mild or moderate severity and benefit from local treatment that represents the mainstay therapy. Topical corticosteroids and vitamin D3 analogues remain the option of choice. Optimization of these treatments is made by the combination of calcipotriene and betamethasone dipropionate. This formulation combines the keratinocyte differentiation and antiproliferative action of the vitamin D3 analogues with the anti-inflammatory effect of steroids enhancing effectiveness while reducing the side-effect profile of the single topical agent. In this article, we highlight the advantages of the association of calcipotriene and betamethasone in the treatment of localized plaque-type, scalp and nail psoriasis.

Original languageEnglish
Pages (from-to)2357-2365
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Issue number14
Publication statusPublished - Oct 2009


  • Betamethasone dipropionate
  • Calcipotriene
  • Nail psoriasis
  • Plaque-type psoriasis
  • Two-compound product

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Calcipotriene/betamethasone in the treatment of psoriasis: A review article'. Together they form a unique fingerprint.

Cite this